Isotope-Enriched 3APS Derivatives for Stable Alzheimer’s Drug Delivery

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing 3-amino-1-propanesulfonic acid (3APS) treatments for Alzheimer's disease face challenges in bioavailability, stability, and metabolism, limiting their therapeutic efficacy.

Innovation Solution

Development of isotope-enriched 3APS derivatives and prodrugs, incorporating deuterium (D) and nitrogen-15 (15N) isotopes, to enhance bioavailability, stability, and reduce metabolism, thereby improving pharmacokinetic profiles.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional 3APS is used for Alzheimer's treatment, then the basic therapeutic effect is achieved, but bioavailability is insufficient and metabolism is rapid

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidbioavailability

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent applies isotope enrichment (deuterium and nitrogen-15) to change the physical and chemical parameters of 3APS, thereby improving its pharmacokinetic properties including bioavailability and reducing metabolism, while maintaining therapeutic efficacy

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates composite molecular structures by combining 3APS with deuterium and nitrogen-15 isotopes, resulting in isotope-enriched derivatives that exhibit improved pharmacokinetic profiles and enhanced therapeutic effectiveness

Inventive Principle:

Principle #40Composite materials

2Reliability

If conventional 3APS is used, then treatment is administered, but stability is poor and metabolism is extensive

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidcompound stability

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

Isotope enrichment with deuterium and nitrogen-15 changes the mass and bond strength parameters of 3APS, increasing compound stability and reducing metabolic degradation while maintaining therapeutic effectiveness

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent converts the natural metabolic vulnerability of 3APS into a benefit by strategically placing deuterium atoms at specific positions to protect against metabolic degradation, transforming the weakness into enhanced stability

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Quantity of substance

If isotope-enriched derivatives are developed, then bioavailability and stability improve, but manufacturing complexity increases

Engineering Contradiction:

ImprovebioavailabilityVSAvoidmanufacturing complexity

Core Design Contradiction:

Quantity of substanceVSDevice complexity

Solution Approach 1:

The patent modifies the molecular parameters of 3APS through isotope enrichment, achieving improved bioavailability and stability while managing manufacturing complexity through systematic approach to isotope incorporation

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The isotope-enriched derivatives increase bioavailability, stability, and reduce metabolism, leading to improved therapeutic effectiveness in treating Alzheimer's disease by enhancing brain levels and reducing side effects.

Implementation Method 1

incorporating deuterium (D) and nitrogen-15 (15N) isotopes, to enhance bioavailability, stability, and reduce metabolism

Methodology Applied

Scientific EffectIsotope enrichment:

Implementation Method 2

Since deuterium (D) has twice the mass of protium (1H), a carbon-deuterium (C-D) bond is stronger than the corresponding carbon-protium (C-1H) bond

Methodology Applied

Scientific EffectCarbon-deuterium bond strengthening:

Implementation Method 3

Such isotope-enrichment can potentially affect a therapeutic agent's metabolism, release from prodrugs and derivatives, absorption, and/or clearance, significantly altering the agent's pharmacokinetic profile

Methodology Applied

Scientific EffectIsotope effect on pharmacokinetics:

Data Source

PatentUS20260035342A1Isotope-enriched 3-amino-1-propanesulfonic acid derivatives and uses thereof

Publication Date: 2026.02.05 RISEN (SUZHOU) PHARMA TECH CO LTD

AI summary

There are provided isotope-enriched compounds of Formula (I) and pharmaceutically acceptable salts or esters thereof, as well as pharmaceutical compositions thereof and methods of use thereof for prevention and treatment and amyloid-β related diseases, such as Alzheimer's disease.